Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.35 |
| ▸ | ELANE | P08246 | 2/20 | 0.34 |
| ▸ | XIAP | P98170 | 1/20 | 0.33 |
| ▸ | BIRC3 | Q13489 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8239022 | 1.00 | DPP8 (0.37) | DPP8DPP9ACEDPP4DPP7 | |
| SCHEMBL4458000 | 0.93 | DPP8 (0.37) | DPP8DPP9DPP4DPP7AGTR2 | |
| SCHEMBL13594519 | 0.93 | DPP8 (0.37) | DPP8DPP9DPP4DPP7AGTR2 | |
| SCHEMBL8230784 | 0.87 | ELANE (0.34) | DPP8DPP9DPP4DPP7ELANE | |
| SCHEMBL8230244 | 0.86 | HTRA1 (0.37) | DPP8DPP9ELANEXIAPBIRC3 | |
| SCHEMBL4407731 | 0.86 | DPP8 (0.38) | DPP8DPP9ACEDPP4DPP7 | |
| SCHEMBL4407736 | 0.86 | DPP8 (0.38) | DPP8DPP9ACEDPP4DPP7 | |
| SCHEMBL4406606 | 0.86 | XIAP (0.33) | DPP8DPP9ELANEXIAPBIRC3 | |
| SCHEMBL4566115 | 0.86 | DPP8 (0.33) | DPP8DPP9DPP4DPP7XIAP | |
| SCHEMBL8189392 | 0.84 | NAMPT (0.34) | DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090304631-A1 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PHENOMIX CORPORATION | 2009-12-10 | — | — | US | disclosed |
| EP-2029153-A2 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | Phenomix Corporation (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007089618-A2 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PHENOMIX CORPORATION (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090304631-A1 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PREP, CTSC, PEPD | DPP8 8/4885DPP9 45/4885ACE 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.